title: Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines.
abstract: We have previously shown that levamisole increases the cytotoxic, cytostatic, and proliferative activity of murine nonparenchymal liver cells (NPC) in vitro. We have also shown that the nonadherent subpopulation of NPC, which are composed predominantly of T lymphocytes, is very responsive to this agent when administered to mice. Kupffer cells or immigrant macrophages are also responsive to levamisole but to a lesser extent. These findings prompted us to investigate changes in cytokine production by NPC following-treatment of mice with levamisole (25 mg/kg, i.p.), which may help explain the observed alterations in the immune functions of these cells. We found that levamisole treatment of mice causes a threefold increase in production of interferon (IFN) alpha/beta by adherent NPC (more than 80%-90% Kupffer cells) in vitro. When IFN alpha/beta was added to cultured cells, it decreased the proliferative capacity of liver T cells in a dose-dependent manner. In contrast, the addition of anti-IFN alpha/beta was shown to augment levamisole-induced proliferation of unfractionated NPC and Kupffer cells. NPC production of interleukin 1 (IL-1) and interleukin-6 (IL-6) in vitro was also increased threefold following treatment of mice with levamisole. IL-6 added in vitro to cells significantly augmented levamisole-induced proliferation of liver T cells while anti-IL-6 reduced proliferative activity to control levels. These findings suggested that IFN alpha/beta, IL-6, and IL-1 play important regulatory roles in controlling the proliferative response of murine liver-associated T lymphocytes to levamisole. Finally, the proliferation of bone marrow cells was increased in mice given 5-fluorouracil (5FU). On the other hand, the proliferation of NPC was dramatically suppressed when 5FU was administered. However, the proliferation of these cells was restored when levamisole was given after 5FU.
authors.affiliation: Department of Surgery, Veterans Administration Medical Center, Buffalo, NY 14215, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Johnkoski
authors.forename: S M
authors.initials: SM
authors.lastname: Peterson
authors.forename: R J
authors.initials: RJ
authors.lastname: Doerr
authors.forename: S A
authors.initials: SA
authors.lastname: Cohen
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D005472:Fluorouracil / Q000494:pharmacology; D007370:Interferon Type I / Q000276:immunology; D007728:Kupffer Cells / Q000187:drug effects / Q000276:immunology*; D007978:Levamisole / Q000494:pharmacology*; D008099:Liver / Q000166:cytology* / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000166:cytology*
chemical_list: D000276:Adjuvants, Immunologic; D007370:Interferon Type I; D007978:Levamisole; D005472:Fluorouracil